WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Options
Query Language
Stem
Sort by:
List Length
Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2010117639) INHIBITION OF PROSTGLANDIN E2 RECEPTORS FOR THE TREATMENT OF ENDOMETRIOSIS
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2010/117639 International Application No.: PCT/US2010/028488
Publication Date: 14.10.2010 International Filing Date: 24.03.2010
IPC:
A61K 31/52 (2006.01) ,A61K 31/5365 (2006.01) ,A61K 31/535 (2006.01) ,A61P 15/12 (2006.01) ,A61P 15/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519
ortho- or peri-condensed with heterocyclic rings
52
Purines, e.g. adenine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
535
having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
5365
ortho- or peri-condensed with heterocyclic ring systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
535
having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
15
Drugs for genital or sexual disorders; Contraceptives
12
for climacteric disorders
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
15
Drugs for genital or sexual disorders; Contraceptives
Applicants: AROSH, Joe, A.[CA/US]; US (UsOnly)
BANU, Sakhila, K.[IN/US]; US (UsOnly)
THE TEXAS A&M UNIVERSITY SYSTEM[US/US]; Office Of Technnology Commercialization M/S 3369 College Station, TX 77843-3369, US (AllExceptUS)
Inventors: AROSH, Joe, A.; US
BANU, Sakhila, K.; US
Agent: CHALKER, Daniel, J.; Chalker Flores, LLP 27 LBJ Freeway Suite 1036 Dallas, TX 75234, US
Priority Data:
12/730,82424.03.2010US
61/165,30231.03.2009US
Title (EN) INHIBITION OF PROSTGLANDIN E2 RECEPTORS FOR THE TREATMENT OF ENDOMETRIOSIS
(FR) INHIBITION DES RÉCEPTEURS DE LA PROSTAGLANDINE E2 POUR LE TRAITEMENT D'UNE ENDOMÉTRIOSE
Abstract:
(EN) The present invention describes the selective inhibition of prostaglandin receptors (PGE2), e.g., EP2 and EP4, by one or more inhibitors are selected from 6-Isopropoxy-9-oxoxanthene-2-carboxylic acid and (4Z)-7-[(rel- l S,2S,5R)-5-((l,l '-Biphenyl-4-yl)methoxy)-2-(4-morpholinyl)-3-oxocyclopentyl]- 4-heptenoic acid and salts thereof as a potential therapeutic tool or to expand the spectrum of currently available treatment options for endometriosis and other chronic gynecological diseases in reproductive age women. PGE2 inhibition through novel cell signaling mechanisms identified by the present invention provides an effective and attractive therapeutic tool for treatment without compromising pregnancy and sex life in the women.
(FR) La présente invention décrit l'inhibition sélective de récepteurs de la prostaglandine (PGE2), par exemple, EP2 et EP4, par un ou plusieurs inhibiteurs qui sont choisis parmi l'acide 6-isopropoxy-9-oxoxanthène-2-carboxylique et l'acide (4Z)-7-[(rel-1S,2S,5R)-5-((1,1'-biphényl-4-yl)méthoxy)-2-(4-morpholinyl)-3-oxocyclopentyl]-4-hepténoique et des sels de ceux-ci en tant qu'outil thérapeutique potentiel ou pour étendre le spectre d'options de traitement actuellement disponibles pour l'endométriose et d'autres maladies gynécologiques chroniques chez des femmes en âge de procréer. L'inhibition de PGE2 par l'intermédiaire de nouveaux mécanismes de signalisation cellulaires identifiés par la présente invention fournit un outil thérapeutique efficace et attractif de traitement sans compromettre la grossesse et la vie sexuelle des femmes.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)